Despite not being statistically significant, this lower baseline count may reflect a greater degree of pre-treatment immunodeficiency, requiring for patients developing TB a more prolonged treatment period for CD4+ cell count to recover [28] and therefore could partially explain the reduced recovery among them. Here, CD4 is linked to immunodeficiency disease.